Figure 2.
Changes in glycated hemoglobin (HbA 1c; mean and SD) at the completion of the double‐blind treatment period for glimepiride monotherapy, alogliptin 12.5 mg and alogliptin 25 mg groups in the full analysis set. ***P < 0.0001 vs placebo.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.